Clinical characteristics of refractory myasthenia gravis patients

Yale Journal of Biology and Medicine

Volumn 86, Issue 2, 2013, Pages 255-260

  Suh, Joome ^a   Goldstein, Jonathan M ^a   Nowak, Richard J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical features; Myasthenia gravis; Refractory disease

Indexed keywords

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYASTHENIA GRAVIS; ONSET AGE; PATIENT CODING; PATIENT IDENTIFICATION; RETROSPECTIVE STUDY; SEX DIFFERENCE; THYMECTOMY; THYMOMA;

CLINICAL FEATURES; MYASTHENIA GRAVIS; REFRACTORY DISEASE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANTIBODIES; FEMALE; HUMANS; MALE; MYASTHENIA GRAVIS; THYMECTOMY; THYMOMA; YOUNG ADULT;

EID: 84879067438     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Drachman DB. Myasthenia gravis. N Eng J Med. 1994;330(25):1797-810.
2. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475-90.
3. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843-54.
4. Silvestri NJ, Wolfe GI. Myasthenia gravis. Semin Neurol. 2012;32(3):215-26.
5. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve. 2010;41(3):375-8.
6. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord. 2011;4(5):259-66.
7. Somnier FE, Keiding N, Paulson OB. Epidemiology of Myasthenia-Gravis in Denmark - a Longitudinal and Comprehensive Population Survey. Arch Neurol. 1991;48(7):733-9.
8. Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann NY Acad Sci. 2008;1132:76-83.
9. Guptill JT, Sanders DB. Update on musclespecific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol. 2010;23(5):530-5.
10. Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann NY Acad Sci. 2008;1132:305-14.
11. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009;16(2):246-50.
12. Prakash KM, Ratnagopal P, Puvanendran K, Lo YL. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience. J Clin Neurosci. 2007;14(3):278-81.
13. Gladstone DE, Brannagan TH 3rd, Schwartzman RJ, Prestrud AA, Brodsky I. High dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry. 2004;75(5):789-91.